Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT04962607
Active, not recruiting Observational

Effectiveness of Premixed Bioactive Bioceramic MTA (Neo-Putty®) in Pulpotomies Primary Teeth

NCT04962607 · tracked via the Priya Life Science Israel tracker
Sponsor
Hadassah Medical Organization
Phase
Observational
Started
2021-09-01
Last updated
2025-06-13

Condition(s) studied

Pulpotomies on Primary Molars

Investigational drug(s) / intervention(s)

Neo-Putty® as dressing agents in pulpotomized primary molars

Neo-Putty® as dressing agents in pulpotomized primary molars: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany). In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM

Study summary

The objective of this prospective randomized clinical trial is to assess clinically and radiographically, the effect of NeoPutty as a pulp medicament following coronal pulp amputation in human primary molars with carious pulp exposure in comparison to Formocresol (FC).

Eligibility

Sex
ALL
Min age
2 Years
Max age
10 Years
Healthy volunteers
Accepted
Inclusion Criteria: * primary teeth which requires pulpotomy. Exclusion Criteria: * not healthy patients, * teeth which requires pulpectomy.

Primary outcome measure(s)

  • Success rate of the primary molar pulpotomy — One year

Trial sites (1)

FacilityCityRegionStatus
Hadassah Medical Organization Jerusalem Israel

More Hadassah Medical Organization trials in Israel

Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects Starting soon
The Computerized Retraining and Functional Treatment - Group Intervention Recruiting
Testis Needle Aspiration of Sperm in Men With Azoospermia Recruiting
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis Active, not recruiting
Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04962607 on ClinicalTrials.gov ↗ ← All trials in Israel